Sign in
Taking peopleNo phase

Tracking low platelet counts over time in antiphospholipid syndrome

Follows changes in platelet counts in adults with antiphospholipid syndrome.

Key facts

Who runs it
New Valley University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort Study
Status
Recruiting
People taking part
200 people, planned
Started
1 Jul 2026
Expected to end
31 Dec 2027
Type of study
Interventional
Treatments tested
  • Platelet count
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a confirmed diagnosis of antiphospholipid syndrome (APS). It follows their platelet counts over time.

Age
18 years and older
Sex
All sexes
Disease stage
Definite APS by Sydney criteria, with blood clots and/or pregnancy problems.
Biomarker or test result
Antiphospholipid antibodies (aPL) must stay positive over time. At least 3 recorded platelet counts over at least 12 months before joining.

Main reasons for not taking part

  • Low platelets clearly caused by something other than APS, such as chemotherapy, myelodysplastic syndromes, cirrhosis or HIV
  • Other conditions that strongly affect survival on their own, such as cancer that has spread, as judged by the study doctor

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Age ≥18 years
  • Definite APS by Sydney criteria (thrombotic and/or obstetric) with persistent aPL positivity
  • ≥3 documented platelet counts over ≥12 months before inclusion (to allow trajectory modeling)

Who cannot take part

  • Concomitant conditions strongly affecting survival independent of APS (e.g., metastatic cancer), at investigator discretion
  • Thrombocytopenia clearly attributable to non APS causes (e.g., chemotherapy, myelodysplastic syndromes, cirrhosis, HIV)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Thrombocytopenia is common in antiphospholipid syndrome (APS) and is now included in the 2023 ACR/EULAR APS criteria as an important non criteria/hematologic feature. Persistent or low-moderate thrombocytopenia independently predicts reduced long-term survival in APS, with hazard ratios for mortality around 2.7-4.4, and is associated with a severe disease phenotype and thrombotic deaths.

The group in the trial

  • Antiphospholipid syndrome patientsTreatment being tested

    * Definite APS by Sydney criteria (thrombotic and/or obstetric) with persistent aPL positivity. * ≥3 documented platelet counts over ≥12 months before inclusion (to allow trajectory modeling)

    Treatment: Platelet count

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Thrombocytopenia Trajectories as a Dynamic Biomarker of Clinical Severity and Survival in Antiphospholipid Syndrome: A Multicenter Cohort Study
Plain-language title
Tracking low platelet counts over time in antiphospholipid syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
28 October 2026